Accessibility Menu
 
Catalyst Pharmaceuticals logo

Catalyst Pharmaceuticals

(NASDAQ) CPRX

Current Price$31.16
Market Cap$3.81B
Since IPO (2006)+411%
5 Year+545%
1 Year+37%
1 Month+23%

Catalyst Pharmaceuticals Financials at a Glance

Market Cap

$3.81B

Revenue (TTM)

$588.99M

Net Income (TTM)

$214.33M

EPS (TTM)

$1.68

P/E Ratio

18.49

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$31.16

Volume

4,480,767.638

Open

$31.14

Previous Close

$31.15

Daily Range

$31.13 - $31.21

52-Week Range

$19.05 - $32.56

CPRX: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Catalyst Pharmaceuticals

Industry

Biotechnology

Employees

182

CEO

Richard John Daly, MBA

Headquarters

Coral Gables, FL 33134, US

CPRX Financials

Key Financial Metrics (TTM)

Gross Margin

85%

Operating Margin

44%

Net Income Margin

36%

Return on Equity

25%

Return on Capital

27%

Return on Assets

19%

Earnings Yield

5.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.81B

Shares Outstanding

122.35M

Volume

4.48M

Avg. Volume

1.73M

Financials (TTM)

Gross Profit

$501.74M

Operating Income

$257.78M

EBITDA

$321.01M

Operating Cash Flow

$208.67M

Capital Expenditure

$58.00K

Free Cash Flow

$208.61M

Cash & ST Invst.

$709.17M

Total Debt

$2.79M

Catalyst Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$152.61M

+7.6%

Gross Profit

$138.54M

+15.3%

Gross Margin

90.78%

N/A

Market Cap

$3.81B

N/A

Market Cap/Employee

$21.06M

N/A

Employees

181

N/A

Net Income

$52.70M

-5.8%

EBITDA

$81.06M

+12.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$706.38M

+37.3%

Accounts Receivable

$128.27M

+95.9%

Inventory

$37.17M

+90.2%

Long Term Debt

$2.35M

-15.6%

Short Term Debt

$437.00K

+8.7%

Return on Assets

19.36%

N/A

Return on Invested Capital

26.86%

N/A

Free Cash Flow

$44.86M

-36.6%

Operating Cash Flow

$44.89M

-36.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BEAMBeam Therapeutics Inc.
$32.32+2.70%
KNSAKiniksa Pharmaceuticals, Ltd.
$58.60+2.93%
IDYAIDEAYA Biosciences, Inc.
$28.32+0.28%
APLSApellis Pharmaceuticals, Inc.
$41.03+0.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
RXTRackspace Technology
$5.49+0.56%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.62+0.08%
IRENIren
$61.20+0.08%
NOKNokia
$12.82+0.04%

Questions About CPRX

What is the current price of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals is trading at $31.15 per share.

What is the 52-week range for Catalyst Pharmaceuticals?

Over the past 52 weeks, Catalyst Pharmaceuticals has traded between $19.05 and $32.56.

How much debt does Catalyst Pharmaceuticals have?

As of the most recent reporting period, Catalyst Pharmaceuticals reported total debt of $2.79M.

How much cash does Catalyst Pharmaceuticals have on hand?

Catalyst Pharmaceuticals reported $709.17M in cash and cash equivalents in its most recent financial results.

What is Catalyst Pharmaceuticals’s dividend yield?

Catalyst Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.